- Home
- MRCC vs CGTX Comparison
MRCC vs CGTX Comparison
Compare MRCC & CGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MRCC | CGTX |
|---|---|---|
| Founded | 2011 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 151.2M | 158.8M |
| IPO Year | 2012 | 2021 |
Fundamental Metrics
Financial Performance| Metric | MRCC | CGTX |
|---|---|---|
| Price | $6.63 | $1.70 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | ★ $8.00 | $2.88 |
| AVG Volume (30 Days) | 100.5K | ★ 1.0M |
| Earning Date | 11-05-2025 | 11-06-2025 |
| Dividend Yield | ★ 15.18% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $43,742,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $5.86 | $0.22 |
| 52 Week High | $8.85 | $3.83 |
Technical Indicators
Market Signals| Indicator | MRCC | CGTX |
|---|---|---|
| Relative Strength Index (RSI) | 57.39 | 53.64 |
| Support Level | $6.36 | $1.58 |
| Resistance Level | $6.55 | $1.81 |
| Average True Range (ATR) | 0.19 | 0.13 |
| MACD | 0.07 | 0.03 |
| Stochastic Oscillator | 98.81 | 79.36 |
Price Performance
Historical ComparisonAbout MRCC Monroe Capital Corporation
Monroe Capital Corp is a speciality finance company focused on providing financing to lower middle-market companies, in the U.S. and Canada. The company provides customized financing solutions focused on senior, unitranche, and junior secured debt and unsecured subordinated debt and equity, including equity co-investments in preferred and common stock and warrants.
About CGTX Cognition Therapeutics Inc.
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.